Dimension Capital, a venture firm established in late 2022, has quickly gained momentum with the recent announcement of its third fund totaling $800 million. This new fund is notably 60% larger than the $500 million second fund it raised just 18 months earlier. Focused on startups operating at the intersection of science and computation, the New York-based firm’s rapid growth highlights rising investor confidence in deep-tech ventures that blend biotech and software innovations.

The firm was co-founded by Zavian Dar and Adam Goulburn, formerly partners at Lux Capital, along with Nan Li from Obvious Ventures, who collectively foresaw founders pushing the boundaries of technology and biology. Their investment strategy has proven prescient, exemplified by their early backing of companies like Chai Discovery and New Limit. Chai Discovery, an AI-driven drug development startup, recently secured $400 million at a $3.8 billion valuation, while New Limit, with Coinbase CEO Brian Armstrong as a co-founder, completed a Series C round valuing the firm at $3.1 billion.

Dimension Capital’s engagement extends to other high-profile companies including Modal Labs and Anthropic. Notably, the firm benefited from Anthropic’s acquisition of its portfolio company Coefficient Bio for $400 million in 2026. These deals illustrate the strong synergy between technological computation advancements and scientific research that fuels the fund’s core investment thesis. The increasing size of Dimension Capital’s funds underscores robust market demand for ventures that merge these disciplines into innovation platforms.

The success of Dimension Capital’s approach, which emphasizes science-intensive startups supported by advances in computation, signals a booming sector attracting substantial capital. As the firm continues to scale rapidly in only four years since inception, its trajectory reflects broader trends in venture capital where interdisciplinary innovation is becoming a primary driver of growth and value creation. For investors and entrepreneurs at the crossroads of biotech and software, Dimension Capital’s third fund embodies the flourishing opportunity space emerging in this dynamic arena.